Trial Profile

Phase III study of HFT-290 in pediatric patients with cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fentanyl (Primary)
Indications Cancer pain
Focus Adverse reactions; Registrational
Sponsors Hisamitsu Pharmaceutical

Most Recent Events

25 Aug 2022 According to a Kyowa Kirin media release, company has received a partial change approval for the additional indications of cancer pain relief for pediatric patients for FENTOS Tapes, transdermal, pain management patch.
16 Nov 2021 Results published in the Clinical Drug Investigation
10 Sep 2020 According to a Hisamitsu Pharmaceutical media release, company has submitted a new drug application for the additional indications of cancer pain relief for pediatric patients for FentosTape in Japan.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com